Skip to main content
SpringerLink
Log in

Current and Emerging Therapies for Atherosclerosis

  • Chapter
  • First Online:
Mechanisms of Vascular Disease

  • 1008 Accesses

Abstract

Atherosclerotic cardiovascular disease remains a leading cause of morbidity and mortality globally. A large body of evidence supports lifestyle measures for primary prevention, and the addition of a statin and/or antiplatelet agents for those at higher risk, or with established disease. Even with these guideline-driven approaches, many individuals continue to experience recurrent events. A number of agents are now emerging to address this ‘residual risk’ and include potent LDL-lowering molecules, pharmaceutical-grade omega-3 fatty acids, glycaemic agents with pleiotropic properties, targeted anti-inflammatories and antithrombotics. As the evidence base for these agents builds, the ongoing challenge remains to determine which patients are likely to derive the most benefit from each additional, specific therapy; a one-size-fits-all approach is not economical, nor is it patient-centred. This chapter describes the current and established therapies for atherosclerosis, provides a summary of the early evidence behind emerging pharmacological therapies and reinforces the need for ongoing development and application of risk assessment tools to facilitate individualised therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–e143. https://doi.org/10.1161/CIR.0000000000000625.

    Article  PubMed  Google Scholar 

  2. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–646. https://doi.org/10.1161/CIR.0000000000000678.

    Article  PubMed  Google Scholar 

  3. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49–73. https://doi.org/10.1161/01.cir.0000437741.48606.98.

    Article  PubMed  Google Scholar 

  4. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737–45. https://doi.org/10.1002/1529-0131(200112)44:12<2737::aid-art460>3.0.co;2-%23.

    Article  PubMed  Google Scholar 

  5. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. 1997;145:408–15. https://doi.org/10.1093/oxfordjournals.aje.a009122.

    Article  CAS  PubMed  Google Scholar 

  6. Triant VA, Perez J, Regan S, Massaro JM, Meigs JB, Grinspoon SK, et al. Cardiovascular risk prediction functions underestimate risk in HIV infection. Circulation. 2018;137:2203–14. https://doi.org/10.1161/CIRCULATIONAHA.117.028975.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Wang Z, Hoy WE. Is the Framingham coronary heart disease absolute risk function applicable to Aboriginal people? Med J Aust. 2005;182:66–9.

    Article  Google Scholar 

  8. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol. 2007;50:217–24. https://doi.org/10.1016/j.jacc.2007.03.037.

    Article  PubMed  Google Scholar 

  9. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34. https://doi.org/10.1056/NEJM199807233390404.

    Article  CAS  PubMed  Google Scholar 

  10. Mahabadi AA, Mohlenkamp S, Lehmann N, Kalsch H, Dykun I, Pundt N, et al. CAC score improves coronary and CV risk assessment above statin indication by ESC and AHA/ACC primary prevention guidelines. JACC Cardiovasc Imaging. 2017;10:143–53. https://doi.org/10.1016/j.jcmg.2016.03.022.

    Article  PubMed  Google Scholar 

  11. Mortensen MB, Fuster V, Muntendam P, Mehran R, Baber U, Sartori S, et al. A simple disease-guided approach to personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage study. J Am Coll Cardiol. 2016;68:881–91. https://doi.org/10.1016/j.jacc.2016.05.084.

    Article  PubMed  Google Scholar 

  12. Williams MC, Hunter A, Shah ASV, Assi V, Lewis S, Smith J, et al. Use of coronary computed tomographic angiography to guide management of patients with coronary disease. J Am Coll Cardiol. 2016;67:1759–68. https://doi.org/10.1016/j.jacc.2016.02.026.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Gupta A, Lau E, Varshney R, Hulten EA, Cheezum M, Bittencourt MS, et al. The identification of calcified coronary plaque is associated with initiation and continuation of pharmacological and lifestyle preventive therapies: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2017;10:833–42. https://doi.org/10.1016/j.jcmg.2017.01.030.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Nelson AJ, Peterson ED, Pagidipati NJ. Atherosclerotic cardiovascular disease and heart failure: determinants of risk and outcomes in patients with diabetes. Prog Cardiovasc Dis. 2019;62:306–14. https://doi.org/10.1016/j.pcad.2019.07.001.

    Article  PubMed  Google Scholar 

  15. Maruthur NM, Wang NY, Appel LJ. Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER trial. Circulation. 2009;119:2026–31. https://doi.org/10.1161/CIRCULATIONAHA.108.809491.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014;34:509–15. https://doi.org/10.1161/ATVBAHA.113.300156.

    Article  CAS  PubMed  Google Scholar 

  17. Johnson HM, Gossett LK, Piper ME, Aeschlimann SE, Korcarz CE, Baker TB, et al. Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial. J Am Coll Cardiol. 2010;55:1988–95. https://doi.org/10.1016/j.jacc.2010.03.002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kondo T, Hayashi M, Takeshita K, Numaguchi Y, Kobayashi K, Iino S, et al. Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol. 2004;24:1442–7. https://doi.org/10.1161/01.ATV.0000135655.52088.c5.

    Article  CAS  PubMed  Google Scholar 

  19. Collaborators GBDT. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017;389:1885–906. https://doi.org/10.1016/S0140-6736(17)30819-X.

    Article  Google Scholar 

  20. He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton PK. Passive smoking and the risk of coronary heart disease—a meta-analysis of epidemiologic studies. N Engl J Med. 1999;340:920–6. https://doi.org/10.1056/NEJM199903253401204.

    Article  CAS  PubMed  Google Scholar 

  21. Micha R, Penalvo JL, Cudhea F, Imamura F, Rehm CD, Mozaffarian D. Association between dietary factors and mortality from heart disease, stroke, and type 2 diabetes in the United States. JAMA. 2017;317:912–24. https://doi.org/10.1001/jama.2017.0947.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Shikany JM, Safford MM, Newby PK, Durant RW, Brown TM, Judd SE. Southern dietary pattern is associated with hazard of acute coronary heart disease in the reasons for geographic and racial differences in stroke (REGARDS) study. Circulation. 2015;132:804–14. https://doi.org/10.1161/CIRCULATIONAHA.114.014421.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Wang DD, Li Y, Chiuve SE, Stampfer MJ, Manson JE, Rimm EB, et al. Association of specific dietary fats with total and cause-specific mortality. JAMA Intern Med. 2016;176:1134–45. https://doi.org/10.1001/jamainternmed.2016.2417.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Jennings G, Nelson L, Nestel P, Esler M, Korner P, Burton D, et al. The effects of changes in physical activity on major cardiovascular risk factors, hemodynamics, sympathetic function, and glucose utilization in man: a controlled study of four levels of activity. Circulation. 1986;73:30–40. https://doi.org/10.1161/01.cir.73.1.30.

    Article  CAS  PubMed  Google Scholar 

  25. Laughlin MH, Bowles DK, Duncker DJ. The coronary circulation in exercise training. Am J Physiol Heart Circ Physiol. 2012;302:H10–23. https://doi.org/10.1152/ajpheart.00574.2011.

    Article  CAS  PubMed  Google Scholar 

  26. Sattelmair J, Pertman J, Ding EL, Kohl HW 3rd, Haskell W, Lee IM. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation. 2011;124:789–95. https://doi.org/10.1161/CIRCULATIONAHA.110.010710.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Spring B, Moller AC, Colangelo LA, Siddique J, Roehrig M, Daviglus ML, et al. Healthy lifestyle change and subclinical atherosclerosis in young adults: coronary artery risk development in young adults (CARDIA) study. Circulation. 2014;130:10–7. https://doi.org/10.1161/CIRCULATIONAHA.113.005445.

    Article  PubMed  PubMed Central  Google Scholar 

  28. White HD, Van de Werf FJ. Thrombolysis for acute myocardial infarction. Circulation. 1998;97:1632–46. https://doi.org/10.1161/01.cir.97.16.1632.

    Article  CAS  PubMed  Google Scholar 

  29. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349:733–42. https://doi.org/10.1056/NEJMoa025142.

    Article  PubMed  Google Scholar 

  30. Roe MT, Ohman EM, Investigators TA. Prasugrel versus clopidogrel for acute coronary syndromes. N Engl J Med. 2013;368:188–9. https://doi.org/10.1056/NEJMc1213509.

    Article  PubMed  Google Scholar 

  31. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57. https://doi.org/10.1056/NEJMoa0904327.

    Article  CAS  PubMed  Google Scholar 

  32. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502. https://doi.org/10.1056/NEJMoa010746.

    Article  CAS  PubMed  Google Scholar 

  33. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–800. https://doi.org/10.1056/NEJMoa1500857.

    Article  PubMed  Google Scholar 

  34. Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Steg PG, Massaro JM, et al. Extended duration dual antiplatelet therapy after coronary stenting among patients with peripheral arterial disease: a subanalysis of the dual antiplatelet therapy study. JACC Cardiovasc Interv. 2017;10:942–54. https://doi.org/10.1016/j.jcin.2017.02.013.

    Article  PubMed  Google Scholar 

  35. Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY, Bavry AA. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J. 2019;40:607–17. https://doi.org/10.1093/eurheartj/ehy813.

    Article  CAS  PubMed  Google Scholar 

  36. McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379:1509–18. https://doi.org/10.1056/NEJMoa1805819.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Nicholls SJ, Nelson AJ. Rivaroxaban with or without aspirin for the secondary prevention of cardiovascular disease: clinical implications of the COMPASS trial. Am J Cardiovasc Drugs. 2019;19:343–8. https://doi.org/10.1007/s40256-018-00322-4.

    Article  CAS  PubMed  Google Scholar 

  38. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000;355:1936–42. https://doi.org/10.1016/S0140-6736(00)02324-2.

    Article  CAS  PubMed  Google Scholar 

  39. Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J. 2006;27:519–26. https://doi.org/10.1093/eurheartj/ehi485.

    Article  CAS  PubMed  Google Scholar 

  40. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513–24. https://doi.org/10.1056/NEJMoa1708454.

    Article  CAS  PubMed  Google Scholar 

  41. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423–34. https://doi.org/10.1056/NEJMoa1611594.

    Article  CAS  PubMed  Google Scholar 

  42. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509–24. https://doi.org/10.1056/NEJMoa1817083.

    Article  CAS  PubMed  Google Scholar 

  43. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319–30. https://doi.org/10.1056/NEJMoa1709118.

    Article  CAS  PubMed  Google Scholar 

  44. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:219–29. https://doi.org/10.1016/S0140-6736(17)32409-1.

    Article  CAS  PubMed  Google Scholar 

  45. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies C. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13. https://doi.org/10.1016/s0140-6736(02)11911-8.

    Article  PubMed  Google Scholar 

  46. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991;265:3255–64.

    Google Scholar 

  47. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial investigators. Lancet. 1997;350:757–64. https://doi.org/10.1016/s0140-6736(97)05381-6.

    Article  CAS  PubMed  Google Scholar 

  48. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. https://doi.org/10.1136/bmj.b1665.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138:e484–594. https://doi.org/10.1161/CIR.0000000000000596.

    Article  PubMed  Google Scholar 

  50. Delacroix S, Chokka RG, Nelson AJ, Nicholls SJ, Worthley SG. Renal denervation: an update. J ATAMIS. 2016;1:5–8.

    Article  Google Scholar 

  51. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–401. https://doi.org/10.1056/NEJMoa1402670.

    Article  CAS  PubMed  Google Scholar 

  52. Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321:364–73. https://doi.org/10.1001/jama.2018.20045.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81. https://doi.org/10.1016/S0140-6736(10)61350-5.

    Article  CAS  Google Scholar 

  54. Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90. https://doi.org/10.1016/S0140-6736(12)60367-5.

    Article  CAS  Google Scholar 

  55. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–8. https://doi.org/10.1056/NEJMoa042378.

    Article  CAS  PubMed  Google Scholar 

  56. Scherer DJ, Nelson AJ, Psaltis PJ, Nicholls SJ. Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors. Intern Med J. 2017;47:856–65. https://doi.org/10.1111/imj.13451.

    Article  CAS  PubMed  Google Scholar 

  57. Ueda Y, Hiro T, Hirayama A, Komatsu S, Matsuoka H, Takayama T, et al. Effect of ezetimibe on stabilization and regression of intracoronary plaque—the ZIPANGU study. Circ J. 2017;81:1611–9. https://doi.org/10.1253/circj.CJ-17-0193.

    Article  CAS  PubMed  Google Scholar 

  58. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97. https://doi.org/10.1056/NEJMoa1410489.

    Article  CAS  PubMed  Google Scholar 

  59. Scherer DJ, Nelson AJ, O’Brien R, Kostner KM, Hare DL, Colquhoun DM, et al. Status of PCSK9 monoclonal antibodies in Australia. Heart Lung Circ. 2019;28:1571–9. https://doi.org/10.1016/j.hlc.2019.04.014.

    Article  PubMed  Google Scholar 

  60. Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376:1430–40. https://doi.org/10.1056/NEJMoa1615758.

    Article  CAS  PubMed  Google Scholar 

  61. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380:1022–32. https://doi.org/10.1056/NEJMoa1803917.

    Article  CAS  PubMed  Google Scholar 

  62. Nicholls SJ, Nelson AJ. HDL and cardiovascular disease. Pathology. 2019;51:142–7. https://doi.org/10.1016/j.pathol.2018.10.017.

    Article  CAS  PubMed  Google Scholar 

  63. Duong M, Nicholls SJ. New drugs for HDL-C disorders: the beginning. Curr Med Chem. 2014;21:2947–51.

    Article  CAS  Google Scholar 

  64. Nicholls SJ. CETP-inhibition and HDL-cholesterol: a story of CV risk or CV benefit, or both. Clin Pharmacol Ther. 2018;104:297–300. https://doi.org/10.1002/cpt.1118.

    Article  PubMed  Google Scholar 

  65. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371:2383–93. https://doi.org/10.1056/NEJMoa1409065.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Di Bartolo BA, Psaltis PJ, Bursill CA, Nicholls SJ. Translating evidence of HDL and plaque regression. Arterioscler Thromb Vasc Biol. 2018;38:1961–8. https://doi.org/10.1161/ATVBAHA.118.307026.

    Article  CAS  PubMed  Google Scholar 

  67. Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. Atherosclerosis. 2011;217:492–8. https://doi.org/10.1016/j.atherosclerosis.2011.04.020.

    Article  CAS  PubMed  Google Scholar 

  68. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22. https://doi.org/10.1056/NEJMoa1812792.

    Article  CAS  PubMed  Google Scholar 

  69. Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, et al. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clin Cardiol. 2018;41:1281–8. https://doi.org/10.1002/clc.23055.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Nicholls SJ, Nelson AJ. The time for lipoprotein(a) based intervention has arrived: where will the light shine? J Thorac Dis. 2019;11:S433–S6. https://doi.org/10.21037/jtd.2018.11.54.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57:1953–75. https://doi.org/10.1194/jlr.R071233.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. O’Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139:1483–92. https://doi.org/10.1161/CIRCULATIONAHA.118.037184.

    Article  CAS  PubMed  Google Scholar 

  73. Nelson AJ, Nicholls SJ. Treating dyslipidemia in type 2 diabetes. Cardiol Clin. 2018;36:233–9. https://doi.org/10.1016/j.ccl.2017.12.005.

    Article  PubMed  Google Scholar 

  74. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–9. https://doi.org/10.1016/S0140-6736(18)32590-X.

    Article  CAS  PubMed  Google Scholar 

  75. Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes and chronic kidney disease in primary and secondary cardiovascular prevention groups: results from the randomized CREDENCE trial. Circulation. 2019;140:739–50. https://doi.org/10.1161/CIRCULATIONAHA.119.042007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139:2022–31. https://doi.org/10.1161/CIRCULATIONAHA.118.038868.

    Article  CAS  PubMed  Google Scholar 

  77. Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392:2180–93. https://doi.org/10.1016/S0140-6736(18)32260-8.

    Article  CAS  PubMed  Google Scholar 

  78. Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL Jr, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018;72:3200–23. https://doi.org/10.1016/j.jacc.2018.09.020.

    Article  PubMed  Google Scholar 

  79. Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404–10. https://doi.org/10.1016/j.jacc.2012.10.027.

    Article  CAS  PubMed  Google Scholar 

  80. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31. https://doi.org/10.1056/NEJMoa1707914.

    Article  CAS  PubMed  Google Scholar 

  81. Benotti PN, Wood GC, Carey DJ, Mehra VC, Mirshahi T, Lent MR, et al. Gastric bypass surgery produces a durable reduction in cardiovascular disease risk factors and reduces the long-term risks of congestive heart failure. J Am Heart Assoc. 2017;6. https://doi.org/10.1161/JAHA.116.005126.

  82. Schwartz AR, Patil SP, Laffan AM, Polotsky V, Schneider H, Smith PL. Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches. Proc Am Thorac Soc. 2008;5:185–92. https://doi.org/10.1513/pats.200708-137MG.

    Article  PubMed  PubMed Central  Google Scholar 

  83. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016;375:919–31. https://doi.org/10.1056/NEJMoa1606599.

    Article  Google Scholar 

  84. Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-based cardiac rehabilitation for coronary heart disease: cochrane systematic review and meta-analysis. J Am Coll Cardiol. 2016;67:1–12. https://doi.org/10.1016/j.jacc.2015.10.044.

    Article  PubMed  Google Scholar 

  85. Martin BJ, Hauer T, Arena R, Austford LD, Galbraith PD, Lewin AM, et al. Cardiac rehabilitation attendance and outcomes in coronary artery disease patients. Circulation. 2012;126:677–87. https://doi.org/10.1161/CIRCULATIONAHA.111.066738.

    Article  PubMed  Google Scholar 

Further Reading

  • Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:219–29. https://doi.org/10.1016/S0140-6736(17)32409-1.

    Article  CAS  PubMed  Google Scholar 

  • Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL Jr, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018;72:3200–23. https://doi.org/10.1016/j.jacc.2018.09.020.

    Article  PubMed  Google Scholar 

  • Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319–30. https://doi.org/10.1056/NEJMoa1709118.

    Article  CAS  PubMed  Google Scholar 

  • Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–e143. https://doi.org/10.1161/CIR.0000000000000625.

    Article  PubMed  Google Scholar 

  • Nicholls SJ, Nelson AJ. HDL and cardiovascular disease. Pathology. 2019;51:142–7. https://doi.org/10.1016/j.pathol.2018.10.017.

    Article  CAS  PubMed  Google Scholar 

  • Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Steg PG, Massaro JM, et al. Extended duration dual antiplatelet therapy after coronary stenting among patients with peripheral arterial disease: a subanalysis of the dual antiplatelet therapy study. JACC Cardiovasc Interv. 2017;10:942–54. https://doi.org/10.1016/j.jcin.2017.02.013.

    Article  PubMed  Google Scholar 

  • Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138:e484–594. https://doi.org/10.1161/CIR.0000000000000596.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke Clinical Research Institute, Monash University, Melbourne, Australia

    Adam J. Nelson

  2. Monash Cardiovascular Research Centre, Monash University, Melbourne, Australia

    Stephen J. Nicholls

Authors
  1. Adam J. Nelson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen J. Nicholls
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen J. Nicholls .

Editor information

Editors and Affiliations

  1. Discipline of Surgery, The University of Adelaide, Adelaide, SA, Australia

    Robert Fitridge

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Nelson, A.J., Nicholls, S.J. (2020). Current and Emerging Therapies for Atherosclerosis. In: Fitridge, R. (eds) Mechanisms of Vascular Disease. Springer, Cham. https://doi.org/10.1007/978-3-030-43683-4_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-43683-4_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-43682-7

  • Online ISBN: 978-3-030-43683-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation